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Abstract
Drug abuse robs individuals of their jobs, their families, and their free will as they
succumb to addiction; but may cost even more: a life of disability or even life
lost due to stroke. Many illicit drugs have been linked to major cardiovascular
events and other comorbidities, including cocaine, amphetamines, ecstasy, heroin,
phencyclidine, lysergic acid diethylamide, and marijuana. This review focuses on
available epidemiological data, mechanisms of action, particularly those leading to
cerebrovascular events, and it is based on papers published in English in PubMed
during1950throughFebruary2011.Eachdrug’suniqueinteractionswiththebrain
and vasculature predispose even young, healthy people to ischemic or hemorrhagic
stroke.Cocaineandamphetamineshavethestrongestassociationwithstroke.How-
ever, the level of evidence ﬁrmly linking other drugs to stroke pathogenesis is weak.
Large epidemiological studies and systematic evaluation of each drug’s action on
the brain and cardiovascularsystem are needed to reveal the full impact of drug use
on the population.
Introduction
Approximately2.2millionpeoplereportedcurrentillicitdrug
use in the 2009 United States National Health Survey (Sub-
stance Abuse and Mental Health Services Administration
2010).Almostonemillionemergencydepartment(ED)visits
intheUnitedStatesinvolvedillicitdrugsin2007(DrugAbuse
Warning Network 2010). Though it is difﬁcult to clearly as-
sociate deaths directly to drug exposure, an estimated 17,000
deaths were attributed to illicit drug use in 2000 (Mokdad
et al. 2004). The major causes of death from drugs are over-
dose, suicide, AIDS, and accidents; however, cerebrovascular
disease is a signiﬁcant source of morbidity from drug use.
Drug use may be the most common predisposing condition
for stroke among patients under 35 years of age. In fact, drug
abusersaged15t o44y earsw er e6.5timesmor elik elyt oha v e
a stroke than nondrug users (Kaku and Lowenstein 1990).
Of 422 patients aged 15–44 with acute ischemicstroke (AIS),
12.1% were found to have recent drug use and 4.7% had
drug abuse as the likely cause of stroke (Sloan et al. 1998).
Lastly, a large population-based study of 1935 patients with
strokediagnosesrevealedthat14.4%ofintracerebralhemor-
rhages(ICH)and14.4%ofAISswereassociatedwithdruguse
(Westover et al. 2007). Despite this obvious connection be-
tween illicit drugs and stroke, epidemiologic data are hard to
ﬁnd.Mostevidencethatillegaldrugsareriskfactorsforstroke
is anecdotal (Brust 2002). Using the data from a number of
case studies and a limited number of population studies, this
article will outline various illicit drugs and their association
to AIS, ICH, and subarachnoid hemorrhage (SAH).
The main illicit drugs associated with stroke are co-
caine, amphetamines, Ecstasy, heroin/opiates, phencyclidine
(PCP), lysergic acid diethylamide (LSD), and cannabis/
marijuana. Tobacco and ethanol are also associated with
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stroke, but will not be discussed here. This article will
outline current epidemiology, pharmacology, evidence re-
lated to strokes, and mechanisms of action related to stroke
risk for each drug listed above. The table summarizes pro-
posed stroke mechanisms for each reviewed drug and stroke
subtype.
Search strategy and selection criteria
References for this review were identiﬁed by searches of
PubMed from 1950 until February 2011 with the terms “is-
chemic stroke,” “intracerebral hemorrhage,” “subarachnoid
hemorrhage,” “illicit drugs,” “substance abuse,” “cocaine,”
“amphetamines,” “heroin,” “marijuana,” “phencyclidine,”
“lysergicaciddiethylamide,”and“Ecstasy.”Articleswerealso
identiﬁed through searches of the authors’ own manuscripts
and relevant publications. Only papers published in English
were reviewed.
Associated Drugs
Cocaine
In the 1970s, recreational use of cocaine became widespread
due to the production of crack cocaine, a purer and cheaper
form of cocaine. The late 1980s saw an epidemic of cocaine:
30 million people of all socioeconomic backgrounds were
cocaine users and 6 million were cocaine addicts (Agarwal
and Sen 2010). In 2009, cocaine was the second-most com-
monly used illicit drug in the United States after marijuana.
Of one million illicit drug-related ED visits yearly in the
United States, nearly half are related to cocaine, making co-
caine the most frequent cause of illicit drug-related ED visits
(The DAWN report 2010).
Pharmacology
Cocaine comes in two chemical forms: the hydrochloride
salt, which is the powdered form of cocaine that is water
soluble, and cocaine alkaloid, a free base that is lipid solu-
ble. The effects of cocaine include local anesthesia, vasocon-
striction, and central nervous system stimulation. Cocaine
preventsneurotransmitter(dopamine,norepinephrine,sero-
tonin, and acetylcholine) reuptake at presynaptic nerve ter-
minals,therebyincreasingtheamountsofneurotransmitters
availableforstimulationofsympatheticnerves.Theeuphoria
relatedtococaineuseisaresultofaccumulationofdopamine
andserotonininthemesolimbicandmesocorticalareasofthe
brain (Treadwell and Robinson 2007). These reward circuits
are related to drug-seeking behavior, addiction, and depen-
dence, making cocaine one of the most potent and highly
addictive chemicals (Goforth et al. 2010).
Cocaine and stroke
As crack cocaine use increased in the 1970s and 1980s, case
reports of cocaine-associated AIS, ICH, and SAH became
more prevalent, which is especially striking given the young
age at which strokes occurred. A review article in the late
1980s found that the mean age of patients with cocaine-
related stroke was 32.5 years (Klonoff et al. 1989).
Case series characterizing the brain location and etiology
of each type of cocaine-related stroke have been performed.
Cocaine-associated AISs have been reported in nearly every
vascular territory in the brain; anterior circulation, poste-
rior circulation, spinal cord, brainstem, and retina have been
affected (Brust 2002). Both cortical and subcortical strokes
can occur (Daras et al.; Jacobs et al. 1989). The etiology of
ischemic infarcts varies as well; large artery, small artery, and
cardioembolic strokes all appear to be of relatively equal in-
cidence (Martin-Schild et al. 2009).
While AIS is far more common than ICH or SAH over-
all, the frequency of hemorrhagic stroke is disproportion-
atelyhighincocaine-relatedstrokes(TreadwellandRobinson
2007). Intracerebral hemorrhages are found throughout the
brain, including basal ganglia, thalamus, lobar, brainstem,
andcerebellarlocations.Whileonestudyfoundmostlylobar
locations (73% of 34 patients) (Kaku and Lowenstein 1990),
a recent study of 45 cocaine users with ICH found predom-
inantly ICH in the basal ganglia (Martin-Schild et al. 2010).
This may depend on the prevalence of underlying hyper-
tension in different populations. The prevalence of underly-
ing vascular lesions in patients with cocaine-related ICH has
been variable, ranging from 10% (Martin-Schild et al. 2010)
to nearly 50% related to ruptured aneurysms or arterio-
venous malformations (AVMs) (Brust 2002; Enevoldson
2004).
Mechanisms of strokes
The main etiologies that have been suggested include hy-
pertensive surges, vasospasm, enhanced platelet aggregation,
cerebralvasculitis,acceleratedatherosclerosis,andcardioem-
bolism (Treadwell and Robinson 2007).
Chronic uncontrolled hypertension is a major risk factor
for stroke. Repeated use of cocaine can raise blood pressure,
increasing the risk for stroke, even in patients who do not
have baseline hypertension. Hypertensive surges may be re-
sponsible for the majority of hemorrhagic strokes associated
with cocaine use.
Vasospasmisafascinatingmechanismforcocaine-induced
stroke. Deﬁned as sudden and usually reversible changes in
vascular caliber due to vascular smooth muscle changes, va-
sospasm is more commonly encountered as a complication
of SAH. A case study of cocaine users, however, found tunica
media and elastic lamina damage in vessels in multiple loca-
tionsinthebrainpossiblyduetochronicvasospasm(Konzen
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et al. 1995). Radiographic studies (Kaufman et al. 1998)
conﬁrmed animal studies (He et al. 1994) that demon-
strated a dose-dependent vasoconstriction of cerebral ves-
sels on magnetic resonance angiography in response to
cocaine.
The pathophysiology of vasospasm in cocaine use is mul-
tifactorial. Cocaine has effects on the calcium channels in
smooth muscle cells in vascular walls. It promotes the re-
lease of calcium from the sarcoplasmic reticulum and also
may allow inﬂux of external calcium into the smooth mus-
cle cells, causing contraction of the vessel walls. Accumu-
lation of catecholamines caused by prevention of reuptake
may result in smooth muscle contraction by an effect on
several receptors in the vessel walls. This latter mechanism
is supported by dopamine antagonist (haloperidol) and cal-
cium channel blocker (verapamil) prevention of vasospasm
in cocaine-exposed smooth muscle cells (He et al. 1994).
Endothelin-1, an endogenous vasoactive peptide, has been
implicated in the development of atherosclerosis and vaso-
constriction.Endothelin-1hasbeendetectedintheurineand
serum of cocaine users. An endothelin-1 antagonist reversed
cocaine-inducedvasospasminanimalmodels(Fandinoetal.
2003). Vasoconstriction may play a role in cocaine-related
stroke even days after last cocaine use. Metabolized by the
liver, cocaine has a half-life of approximately 1 hour, but ma-
jor provasoconstrictive metabolites can last for days. There
is also large variation among individuals, with metabolites
lingering in chronic users for up to 3 weeks (Enevoldson
2004).
Vasospasm may cause endothelial injury, resulting in in-
timal hyperplasia and platelet activation and aggregation,
ultimately occluding vessels (Treadwell and Robinson 2007).
This may be why microvascular white matter changes are
found on MRI in chronic cocaine users (Volkow et al.
1988; Goforth et al. 2010). Cocaine administration activates
platelets resulting in α-granule release and the formation of
platelet-rich microaggregates (Heesch et al. 2000). It also
increases platelet responsiveness to arachidonic acid, and
causes the release of thromboxane β2 and plasminogen acti-
vatingfactor-1inhibitor(PAI-1).Allofthesefactorspromote
platelet aggregation (Togna et al. 1985; Kolodgie et al. 1995)
and facilitation of thrombus formation.
Very few cases of biopsy-proven vasculitis associated with
cocaine exposure have been reported. These cases describe a
hypersensitivity-typevasculiticmorphologythatdiffersfrom
the typical inﬂammatory central nervous system vasculitis.
Supporting this is the fact that in cases of presumed cocaine-
induced vasculitis, steroids failed to improve the patient’s
symptomsintheshortterm(Merkeletal.1995).Moststudies
have failed to demonstrate these ﬁndings on autopsy (Brust
2002; Enevoldson 2004).
Cocaine may promote accelerated atherosclerosis, leading
tolongertermincreasedriskforAISincocaineusers.Rabbits
with high cholesterol that were exposed to cocaine demon-
strated a greater extent of cholesterol plaque in the proximal
thoracic aorta than control rabbits (Kolodgie et al. 1993). In
the presence of cocaine, cell membranes are more permeable
toatherogeniclipoproteins(Kolodgieetal.1993,1995,1999).
Cardioembolism is a well-known cause of cocaine-related
stroke. Mechanisms of embolism and ischemic stroke in-
clude infective endocarditis in patients who inject co-
caine hydrochloride, arrhythmia, acute and chronic di-
lated cardiomyopathy, and myocardial infarction (Sloan and
Mattioni1992).Cocaineuseishighlyassociatedwithinfective
endocarditis: in one study of drug users with endocarditis,
79% were cocaine users (Chambers et al. 1987). In addi-
tion to embolization,endocarditiscan cause a septic cerebral
arteritis. Endocarditis provokes ICH from rupture of my-
coticaneurysmsandhemorrhagictransformationofembolic
stroke(Hartetal.1987;Enevoldson2004;HaganandBurney
2007).
Hypertensivesurgewithorwithoutanunderlyingvascular
malformation is the most common implicated etiology for
ICH and SAH. The indirect sympathomimetic effects of co-
caine transiently raise the systolic blood pressure, which can
cause spontaneous bleeding in existing AVMs, aneurysms,
or areas of old ischemic strokes, or may actually facilitate
aneurysm formation (Nolte et al. 1995). Cocaine users with
ICH have very high blood pressure on admission (Martin-
Schild et al. 2009), and have blood in classic hypertensive
locations. Brainstem hemorrhages were over-represented in
patients with cocaine-associated ICH. Cocaine users with
ICH have worse short-term functional outcome compared
to patients with hemorrhage who are not cocaine users. In
fact,cocaineuserswithICHwerenearlyﬁvetimesmorelikely
to be dependent and three times more likely to die than pa-
tientswithICHwhodidnotusecocaine(Martin-Schildetal.
2010). When SAH occurs in cocaine users, aneurysms are
often detected on angiography (Oyesiku et al. 1993; Fessler
et al. 1997).
Amphetamines
WidespreadamphetamineabusebeganduringWorldWarII,
when it was offered to soldiers to ﬁght fatigue and improve
morale. By the 1950s, there was an upswing in legal prescrip-
tion of amphetaminesin the United States. The manufacture
and distribution of amphetamines was greatly reduced af-
ter the passage of the Controlled Substances Act in 1970.
In the late 1980s and 1990s, however, amphetamines were
back in vogue, due to the ease and low expense of synthesiz-
ing methamphetamines in amateur laboratories. As of 2000,
anestimated35millionpeopleabusedamphetaminesworld-
wide,ascomparedwith15millioncocaineabusers(Albertson
et al. 2007).
c   2011 The Authors. Published by Wiley Periodicals, Inc. 47K. Esse et al.
Pharmacology
Amphetamines constitute a group of drugs with chemical
similarity to the natural neurotransmitters epinephrine and
dopamine. Synthetic modiﬁcations result in differing effects
and properties. Each is a weak base and can be absorbed
via multiple routes. Depending on the particular drug and
dosage, the half-life can range from 10 to 30 hours. Metham-
phetamine (meth) is the most potent of amphetamines and
is most commonly abused; it has a half-life of 12 hours, is
metabolized through the liver, and has an active metabolite
which is a potent hallucinogen.
Amphetamines block the presynaptic reuptake of the cat-
echolamines dopamine, norepinephrine, and serotonin, al-
lowing these neurotransmitters to remain in the synapse to
triggerandsaturatethepostsynapticreceptors.Theuserfeels
euphoric and experiences increased motor movements, in-
creasedproductivity,decreasedappetite,andincreasedlibido
(Albertson et al. 1999; Winslow et al. 2007; Freye and Levy
2009).Amphetaminescreatestrongeffectsofaddiction,crav-
ing, and tolerance in chronic users (Freye and Levy 2009).
Amphetamineshavewide-rangingeffectsonnearlyeveryor-
gan system. Amphetamines have been linked to myocardial
infarction, cardiomyopathy, renal failure, liver failure, respi-
ratory failure, stroke, memory loss, confusion, and a many
psychiatric symptoms.
Amphetamines and stroke
Amphetamine use increases the odds of stroke by almost
four times that of nonusers (Petitti et al. 1998) and results in
greater disability and mortality rates (Westover et al. 2007).
AIS,ICH,andSAHshavebeenreportedintheliterature.Most
case series report a disproportionate rate of hemorrhagic
s t r o k ewi t ha m p h e t a m i n eu s e ,u pt ot wi c et h er i s ko fc o c a i n e
(odds ratio 4.95 vs. 2.33) (Westover et al. 2007).
Mechanisms of stroke
Amphetamines, like cocaine, are sympathomimetic. There-
fore,themechanismsofstrokeinamphetamineusersaresim-
ilartothoseofcocaine-relatedstrokes.Upto75%ofpatients
with methamphetamine-related stroke have signiﬁcantly el-
evated blood pressures on arrival (Perez et al. 1999). Am-
phetamines may accelerate hypertensive heart disease with
myocardial hypertrophy and interstitial ﬁbrosis and cause
direct myocardial toxicity with contraction-band necrosis
(Yeo et al. 2007; Yi et al. 2008; Ito et al. 2009). Cardiomy-
opathy is a well-established complication of amphetamine
abuse. Methamphetamine use is associated with a 3.7-fold
increase in the odds of detecting cardiomyopathy (95% con-
ﬁdenceinterval:1.8–7.8)(Yeoetal.2007).Methamphetamine
users with cardiomyopathy have lower left ventricular ejec-
tionfractionsandhigherend-diastolicandleftatrialvolumes
than heart failure patients without methamphetamine use
(Ito et al. 2009). Cardiomyopathy results in arrhythmias and
thrombosis, leading directly to cardio-embolic strokes.
Unlike cocaine, an association between chronic am-
phetamine use, stroke and vasculitis have been reported.
Angiography in multidrug abusers detected ﬁndings con-
sistent with necrotizing periarteritis in multiple organs on
angiography, and conﬁrmed those ﬁndings, speciﬁcally in
the central nervous system on autopsy of select cases. Am-
phetamines were the most commonly abused drug in these
studies(Citronetal.1970;HalpernandCitron1971;Margo-
lis and Newton 1971; Stafford et al. 1975; Wooten et al. 1983;
Salanova and Taubner 1984; Shibata et al. 1991; Brust 1997;
Ho et al. 2009).
Acute increase in systolic blood pressure during am-
phetamineuseleadstospontaneousICH(McGeeetal.2004).
In fact, hemorrhagic strokes have been observed after only a
single use of amphetamines (Stoessl et al. 1985). Most cases
ofICHinvolvebrainregionscommonlyaffectedinhyperten-
sive ICH (Ho et al. 2009). Histopathological evidence sup-
port that repeated amphetamine abuse can result in blood
vessel injury, leading to vessel wall necrosis, microinfarcts in
smallvessels,andatherosclerosis(McGeeetal.2004;Hoetal.
2009). Amphetamine-related SAHs mostly frequently report
underlying aneurysms (Ho et al. 2009; Kaku and Lowenstein
1990).
Ecstasy
Ecstasy is a nonspeciﬁc name for a variety of “designer
drugs” used mainly by young adults. They are deriva-
tives of amphetamine. The majority of Ecstasy in use
is 3,4-methylenedioxymeth-amphetamine, or MDMA, N-
ethyl-3,4-methylenedioxyamphetamine or MDEA (some-
times called “Eve”), or 3.4-methylenedioxyamphetamine
(MDA). Recent epidemiological data indicate that Ecstasy
use is increasing among college students (Strote et al. 2002).
Pathophysiology
ThoughEcstasyisderivativeofamphetamine,thedrugmore
closely resembles the hallucinogen mescaline, rendering it
to be a blend of hallucinogenic and catecholaminergic ef-
fects. Ecstasy increases the release of, and inhibits the reup-
takeof,serotoninandnorephinephrine,withlessereffectson
dopamine. The toxicity, time course, and intensity of reac-
tion can differ signiﬁcantly between preparations. The drug
is usually ingested in pill form, metabolized by the liver, and
generally achieves peak concentration in the blood approxi-
mately two hours after ingestion.
Ecstasy and stroke
There are no epidemiological studies speciﬁcally studying
the incidence of Ecstasy-related strokes. There are a small
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number of case studies of both ischemic and hemorrhagic
strokes occurring within hours of ingestion of Ecstasy
(Hugheset al. 1993;Harriesand De Silva1992;Gledhill et al.
1993; Manchanda and Connolly 1993; Hanyu et al. 1995;
Kalant 2001; Auer et al. 2002).
Mechanisms of stroke
ThevasculardistributionofAISsrelatedtoEcstasyuseisvari-
able. The possible etiologies of MDMA-induced stroke are
similartothoseofcocaine-andamphetamine-relatedstrokes.
Cardiacarrhythmias,havebeenimplicatedinEcstasy-related
cardiac death, and are potential causes of Ecstasy-related
stroke via cardioembolism (Hughes et al. 1993). Cardiomy-
opathy has also been described in Ecstasy users and is associ-
ated with congestive heart failure, arrhythmia, and stroke.
After exposure to Ecstasy, vasospasm and necrosis have
been observed in the vasculature of the globus pallidus and
occipitalcortex,makingdamagefromAISmostlikelyinthese
areas (Reneman et al. 2000; Rojas et al. 2005; Hagan and
Burney 2007). Damage to the vessel walls over time from
chronicvasospasmandnecrosismayalsoleadtoboththrom-
bosis and aneurysmal dilatation of cerebral vessels. This can
thenleadtoAIS,ICH,orSAH(Kalant2001;Aueretal.2002).
Ecstasy increases the bioavailability of serotonin, a potent
vasoconstrictive amine, which decreases cerebral blood ﬂow
andcanleadtocerebralinfarction(Hanyuetal.1995).Long-
term use of Ecstasy results in decreased overall serotonin
availability and vasodilation, and even ICH in the setting of
hypertension (Reneman et al. 2000).
Highfever,provokedbyEcstasy’sactivationofthehypotha-
lamus, may trigger the clotting cascade, resulting in dissem-
inated intravascular coagulation and microinfarcts through-
o u tt h eb o d y ,i n c l u d i n gt h eb r a i n ,a sw e l la sb l e e d i n gd u e
to consumptive coagulopathy (Kalant 2001; Freye and Levy
2009). Very little evidence supports vasculitis as a complica-
tion of Ecstasy use (Manchanda and Connolly 1993).
Hypertensive surge may lead to small-vessel ICH or large-
vessel hemorrhage via rupture of an underlying cerebrovas-
cular malformation. Esctasy-related ICH occurs in regions
commonly affected by hypertension, and SAH is usually as-
sociated with an underlying aneurysm.
Opiates/Heroin
Heroinisasemi-syntheticderivativeofopium.Heroinaddic-
tion became a problem around the turn of the 20th century.
The United States Department of Health and Human Ser-
vices’ National Household Survey on Drug Abuse Study esti-
mated that in 2008, 3.8 million people over the age of 12 had
used heroin during their lifetime. In 2009, 180,000 people in
the United States used heroin for the ﬁrst time, representing
a signiﬁcant increase from prior years (Substance Abuse and
Mental Health Services Administration 2010).
Pharmacology
Heroinbindstoendogenousopiatereceptors(mu,kappa,and
delta) located throughout the body, including the brain and
the spinal cord. The mu receptor is responsible for analgesia,
euphoria,nervoussystemdepression,respiratorydepression,
and constipation. Heroin, unlike morphine, is able to cross
the blood–brain barrier very easily. Heroin tends to cause
hypotension from decreased peripheral vascular resistance,
bradycardia by inhibiting the baroreceptor reﬂex, and res-
piratory depression by slowing the brain’s response to high
CO2 and low oxygen levels. When heroin is injected, the ini-
tial effect, or “rush,” occurs within a few minutes and peaks
at around 10 minutes. After this, sedation ensues and lasts
about one hour.
Stroke and heroin
Heroinandotheropiatesareknowntocauseseveremorbidity
anddeathfromviolence,overdose,AIDS,suicide,andsepsis.
However,strokes associatedwithheroin/opiateusearerarely
reported.Despitethisscarcereporting,opiateswere16times
less likely to cause hemorrhagic strokes and ﬁve times less
likelytocauseischemicstrokethanamphetamines(Westover
etal.2007).Mostreportedstrokesassociatedwithheroinuse
are ischemic (Hagan and Burney 2007).
Mechanisms of stroke
Heroin-associated stroke is most often due to cardioem-
bolism in the setting of infective endocarditis (Hagan and
Burney 2007). Another source for embolic disease from
heroin use is foreign bodies that have been added to the
heroin. Foreign bodies (potentially including starch, sugar,
Ajax, quinine, lactose, mannitol, caffeine, aspirin, lidocaine,
strychnine,andtalcumpowder)enterthecirculationandbe-
come lodged in the lungs. A granulomatous reaction leads to
pulmonary hypertension, causing or exacerbating right-to-
leftpulmonaryshuntspredisposingtocardioembolicstrokes
(Brust 1989; Lucas 2005).
Arteritisandvasculitishavealsobeenindirectlyimplicated
as a cause of heroin-related strokes. “Beading” on angiogra-
phy along with supporting laboratory studies has been re-
ported, but pathological evidence supporting this theory is
lacking (Brust 1997) and it is not known if the vessel changes
are in response to the heroin itself or adulterants. Other
potential causes of stroke include hypotension and hypox-
emia induced by opiate overdose; these can result in global
hypoxic-ischemic injury to classically vulnerable areas of the
brain (Andersen and Skullerud 1999).
Phencyclidine (PCP)
Phencyclidine, known as PCP, is classiﬁed as a dissocia-
tive anesthetic similar to ketamine. The drug was initially
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introduced as an anesthetic that did not paralyze the di-
aphragm or cause respiratory depression, but it was pulled
from the market due to reports of adverse neuropsychiatric
reactions after anesthesia. PCP use has declined over time
(LernerandBurns1978;Gahlinger2004).Thelifetimepreva-
lence of PCP use in the United States was estimated at ap-
proximately 6.6 million people over the age of 12 (Substance
Abuse and Mental Health Services Administration 2010).
Pharmacology
The full range of PCP effects on the brain are incom-
pletelyunderstood,duetoeffectsonmultipleneurotransmit-
ter pathways and receptors including N-methyl D-aspartate
(NMDA) (antagonist) nicotinic acetylcholine (antagonists)
and dopamine (agonist). Complicating the picture fur-
ther, PCP may have its own receptors on cerebral vessels
(Altura et al. 1983). Since PCP is stored in the body’s fat,
re-mobilization from those stores can cause recurrent symp-
tomsfordaystomonths.PCPismetabolizedbytheliver ,and
has multiple metabolites. Ten percent of the dose of phency-
clidine is excreted unchanged in the urine, and can be picked
up by a urine drug screen (Domino 1978; Gahlinger 2004;
West et al. 2011).
PCP and Stroke
A total of ﬁve cases of PCP-associated stroke were found in
the literature—all of them were hemorrhagic. PCP’s sympa-
thomimetic hypertensive effect may be the provoking factor.
Hypertension is one of the primary clinical ﬁndings in PCP
intoxication (McCarron et al. 1981). Spikes of severe hyper-
tension can occur hours to days after use. PCP-related SAH
has been reported and may result from weakening of arterial
walls (Boyko et al. 1987). While vasospasm can be provoked
in vitro by PCP (Altura et al. 1983) in a dose-dependent
manner at concentrations paralleling those of patients who
overdosedonthedrug,therearenoreportedcasesconﬁrming
vasospasm in association with stroke in PCP users.
LSD
Lysergic acid diethylamide, or LSD, is a potent hallucinogen.
During the 1950s to 1970s, the psychiatric community ex-
tensively explored the use of LSD to treat psychosis, alcohol
addiction, autism, and criminal behavior. Its current popu-
larity is declining: the number of new users dropped from
958,000 in 2000 to 337,000 in 2009 (Mechem and Hall 2008;
SubstanceAbuseandMentalHealthServicesAdministration
2010).
LSD and Stroke
OnlyfourcasesofstrokerelatedtoLSDhavebeenreportedin
the literature. All of the cases involved AIS in patients under
the age of 25 (Sobel et al. 1971; Lieberman et al. 1974). The
twocasesinwhichLSDwasthesoledrugusedbythepatients
werecasesthatinvolvedlarge-arteryocclusions.Similartoer-
got alkaloids, LSD affects serotonin receptors and may cause
vessel constriction. In vitro, LSD produces signiﬁcant va-
sospasm of cerebral arteries; this effect is reversed by a 5-HT
antagonist(methysergide)oracalciumchannelblocker(ver-
apamil) (Altura and Altura 1981). Given the apparent ability
of LSD to cause vasospasm in vitro, it is more likely that
a vasospastic process is responsible for LSD-related strokes
(Altura and Altura 1981).
Marijuana
Marijuana is the most commonly used recreational drug in
the United States, and 15 states have approved marijuana for
medicaluse(StateMedicalMarijuanaLaws2010).Morethan
16.7 million people reported marijuana use within the past
month on a national survey conducted in 2009 (Substance
Abuse and Mental Health Services Administration 2010).
Marijuana and Stroke
Evidencesupportingmarijuana’sroleinstrokeisscarce,con-
sideringitswidespreaduse.Onestudydemonstratedanodds
ratio for AIS with marijuana use of 1.76 (95% conﬁdence in-
terval1.15–2.71),evenwhencontrollingforotherriskfactors
(Kaku and Lowenstein 1990). Twenty-one cases of imaging-
positive stroke related to marijuana use have been reported
(Cooles and Michaud 1987; Zachariah 1991; Barnes et al.
1992; Lawson and Rees 1996; McCarron and Thomas 1997;
Mouzak et al. 2000; Mesec et al. 2001; Mathew et al. 2003;
Finsterer et al. 2004; Geller et al. 2004; Moussouttas 2004;
Mateo et al. 2005; Aryana and Williams 2007; Duchene et al.
2010; Renard et al. 2010). Twenty were ischemic infarcts in
men; one was an ischemic infarct in a woman (Duchene
et al. 2010). No consistent pattern of infarct distribution was
identiﬁed.
Proposed mechanisms for marijuana-associated cerebral
infarction include hypotension, vasospasm, and arrhythmia
with resulting cardioembolism (Cooles and Michaud 1987;
Mathew et al. 2003; Geller et al. 2004; Moussouttas 2004;
Mateo et al. 2005; Aryana and Williams 2007). Since these
phenomena are often transient, the direct role in stroke is
elusive. Cannabinoids have a role in cerebral autoregulation,
vascular tone, and cardiac pathology (Mittleman et al. 2001;
Mathew et al. 2003; Moussouttas 2004) and may provoke the
reversible vasoconstriction syndrome associated with thun-
derclap headache, SAH, ICH, and cerebral ischemia (Ducros
et al. 2007).
Conclusion
Illicit drugs are used by millions of people every day. Based
onanextensivereviewofthemedicalliterature,itisapparent
that these illicit drugs are dangerous for many reasons, and
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some of them appear to increase a person’s risk for both is-
chemic and hemorrhagic strokes. The evidence is fairly clear
thatcocaineandamphetaminesarestronglylinkedtostroke,
butEcstasy,opiates,phencyclidine,LSD,andmarijuanasim-
p l yd on o th a v et h eb u r d e no fe v i d e n c er e q u i r e dt oﬁ r m l y
link usage to stroke pathogenesis. Unfortunately, the lack of
standardization and the propensity for many of these drugs
tobemixedwithadulterantshasmuddiedthepictureofhow
these drugs act in the body. Further, the study of illicit drugs
is hampered by the need for patient or surrogate disclosure
or reliance on urine toxicology for which commonly used
medications may result in a falsely positive urine drug test
(Brahm et al. 2010). Regardless, future studies are needed
to systematically evaluate how each of these chemicals acts
on the cerebrovascular system. In addition, the lack of epi-
demiological studies on drugs and stroke hinders the ability
of researchers to gain perspective on the impact that drug
use may have on the population. Going forward, research
on illicit drugs and their relationship to stroke and other
morbiditiesis a responsibilitythat cannotbe denied by those
devoted to reducing the burden of stroke and cardiovascular
health on society.
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